"In September 2010, Novartis pled guilty to marketing Trileptal for the unapproved uses of neuropathic pain and bipolar disorder during 2000 and 2001." U.S. District Court for the Eastern District of Pennsylvania. "Government’s memorandum for entry of plea and sentencing"